8-K
filed June 21, 2023, 7:59 PM ET
ticker LYEL
CIK 0001806952
other
confidence high
sentiment neutral
materiality 0.15
Lyell Immunopharma shareholders elect 3 directors, ratify EY, approve say-on-pay annually
Lyell Immunopharma, Inc.
- Three Class II directors elected: Klausner (150.6M for), Brawley (143.1M for), Rieflin (150.0M for).
- Ernst & Young LLP ratified as auditor for FY 2023 with 187.8M votes for, 16.9K against.
- Say-on-pay approved with 131.5M votes for, 3.3M against, 19.2M abstentions; broker non-votes 33.9M.
- Advisory vote on frequency: 143.0M preferred every 1 year; Board adopted annual say-on-pay policy.
- Say-on-pay frequency policy in effect until next required vote no later than 2029 annual meeting.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Lyell Immunopharma, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-16 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-16
Exact text from the filing
To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The voting results were as follows: Votes For Votes Against Abstentions Total 187,794,458 16,913 39,312 187,850,683
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Lyell Immunopharma, Inc. shareholders approved Advisory vote to approve compensation of named executive officers at the 2023-06-16 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-06-16
Exact text from the filing
To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes Total 131,476,834 3,278,721 19,180,844 33,914,284 187,850,683
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Lyell Immunopharma, Inc. shareholders approved Advisory vote on preferred frequency of stockholder advisory votes on executive compensation at the 2023-06-16 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2023-06-16
Exact text from the filing
To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes to approve the compensation of the Company’s named executive officers. The voting results were as follows: Vote For Every One Year Vote For Every Two Years Vote For Every Three Years Abstentions Broker Non-Votes Total 142,962,684 695 33,332 10,939,688 33,914,284 187,850,683
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Lyell Immunopharma, Inc. shareholders approved Election of three Class II directors at the 2023-06-16 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-16
Exact text from the filing
To elect the following three Class II directors to hold office until the Company’s 2026 annual meeting of stockholders. The voting results were as follows: Name Votes For Votes Withheld Broker Non-Votes Total Richard Klausner, M.D. 150,646,318 3,290,081 33,914,284 187,850,683 Otis Brawley, M.D. 143,059,192 10,877,207 33,914,284 187,850,683 William Rieflin 150,032,005 3,904,394 33,914,284 187,850,683
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.